CytoDyn Secures Funding for Leronlimab Expanded Access Program in Breast Cancer

CytoDyn Inc. (CYDY) announced on January 27, 2026 that it secured funding to launch an expanded access program for its drug candidate leronlimab in metastatic breast cancer. The program will provide the investigational treatment to eligible patients outside clinical trials while the company continues its regulatory development process. The funding source and specific financial terms were not disclosed. Leronlimab is a CCR5 antagonist being developed for multiple cancer indications and HIV. CytoDyn's stock has been volatile amid ongoing regulatory interactions and previous clinical trial results.